Previous 10 | Next 10 |
home / stock / me / me articles
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results. Compass Minera...
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.29% to 38...
Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankrupt...
In a recent announcement, 23andMe Holding Co. (NASDAQ:ME) has disclosed that the U.S. Food and Drug Administration (FDA) has given the green light ...
SUNNYVALE, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading genetic health and biopharmaceutical c...
Genetic testing company 23andMe Holding Co. (NASDAQ:ME) is under fire in a class action lawsuit, accused of inadequately protecting the privacy o...
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharma...
Editor’s note: The headline of this story has been updated to reflect that 23andMe ancestry data was hacked — not DNA data. In a significa...
In a significant security breach, genetic testing company 23andMe Holding Co. (NASDAQ:ME), confirmed that hackers have accessed around 14,000 cus...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Hea...
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at h...
2024-06-04 12:48:12 ET Genetic database builder 23andMe (NASDAQ: ME) stock slid 10% through 12:05 p.m. ET Tuesday. Curiously, though, the news that 23andMe reported today seemed generally of the "good" variety. The company announced a collaboration with the nonprofit Colorectal ...